● Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Condition: ER+ HER2- Advanced Breast Cancer · High-grade Serous Ovarian Cancer (HGSOC) · Sponsor: AstraZeneca

PhasePhase 1/Phase 2

Planned participants564

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (14)

Research Site	St Louis, Missouri, United States	Recruiting
Research Site	Providence, Rhode Island, United States	Recruiting
Research Site	Nashville, Tennessee, United States	Recruiting
Research Site	Houston, Texas, United States	Recruiting
Research Site	East Melbourne, Australia	Recruiting
Research Site	Seoul, South Korea	Recruiting
Research Site	Seoul, South Korea	Recruiting
Research Site	Barcelona, Spain	Recruiting
Research Site	Pamplona, Spain	Recruiting
Research Site	Valencia, Spain	Recruiting
Research Site	Cambridge, United Kingdom	Recruiting
Research Site	Leeds, United Kingdom	Recruiting

+ 2 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06188520